Social Media Posted January 18, 2023 Share Posted January 18, 2023 Moderna Inc. announced on Tuesday that a late-stage trial found that its experimental messenger RNA vaccine for respiratory syncytial virus was 83.7% effective in preventing at least two symptoms in adults ages 60 and older. RSV produces symptoms similar to a cold and can lead to death for young children and older adults. It results in about 14,000 deaths per year in adults who are at least 65-years-old. RSV, the flu and coronavirus all soared in the U.S. and Europe this fall. There is no vaccine for adults currently on the market, but Moderna, Pfizer Inc. and GSK Plc. are each looking to be the first to release their RSV vaccines. 1 Link to comment Share on other sites More sharing options...
Eleftheros Posted January 19, 2023 Share Posted January 19, 2023 All these wonderful numbers from Big Pharma are regularly declared like the Soviet tractor production figures .... Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now